BlackRock Institutional Trust’s CASI Pharmaceuticals CASI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$259K Hold
22,565
– – ﹤0.01% 3560
2016
Q3
$250K Hold
22,565
– – ﹤0.01% 3591
2016
Q2
$264K Hold
22,565
– – ﹤0.01% 3599
2016
Q1
$239K Hold
22,565
– – ﹤0.01% 3593
2015
Q4
$217K Hold
22,565
– – ﹤0.01% 3641
2015
Q3
$241K Hold
22,565
– – ﹤0.01% 3618
2015
Q2
$404K Hold
22,565
– – ﹤0.01% 3542
2015
Q1
$333K Buy
22,565
+151
+0.7% +$2.38K ﹤0.01% 3572
2014
Q4
$298K Hold
22,414
– – ﹤0.01% 3596
2014
Q3
$401K Buy
+22,414
New +$399K ﹤0.01% 3524
2014
Q2
– Sell
-22,414
Closed -$408K – 3947
2014
Q1
$408K Hold
22,414
– – ﹤0.01% 3604
2013
Q4
$375K Hold
22,414
– – ﹤0.01% 3627
2013
Q3
$403K Sell
22,414
-78
-0.3% -$1.48K ﹤0.01% 3559
2013
Q2
$454K Buy
+22,492
New +$436K ﹤0.01% 3508

Other funds holding CASI

BlackRock Institutional Trust's CASI Position: Q4 2016 in Review

BlackRock Institutional Trust held its CASI Pharmaceuticals (CASI) position steady in Q4 2016 at 22,565 shares worth $259K. The position accounts for ﹤0.01% of the portfolio, ranked #3560.

BlackRock Institutional Trust first reported a position in CASI in Q2 2013 and has held it in 14 quarters since. The position peaked at $454K in Q2 2013. 28 funds tracked by Wall St. Rank hold CASI as of Q4 2016.

  • BlackRock Institutional Trust held 22,565 shares of CASI Pharmaceuticals worth $259K as of Q4 2016.
  • BlackRock Institutional Trust left its CASI Pharmaceuticals share count unchanged in Q4 2016.
  • CASI Pharmaceuticals made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3560 holding.
  • BlackRock Institutional Trust first reported a position in CASI Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
  • BlackRock Institutional Trust's CASI Pharmaceuticals position peaked at $454K in Q2 2013.
  • 28 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.